Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRN017
MIFTS: 45

Coronary Thrombosis

Categories: Blood diseases, Cardiovascular diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Coronary Thrombosis

About this section

MalaCards integrated aliases for Coronary Thrombosis:

Name: Coronary Thrombosis 11 53 43 14 16 71 75
Coronary Artery Thrombosis 11

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:11847
MeSH 43 D003328
SNOMED-CT 68 66514008
ICD10 31 I22
UMLS 71 C0010072
Sources

Summaries for Coronary Thrombosis

About this section

MalaCards based summary: Coronary Thrombosis, also known as coronary artery thrombosis, is related to heparin-induced thrombocytopenia and factor viii deficiency. An important gene associated with Coronary Thrombosis is PLAT (Plasminogen Activator, Tissue Type), and among its related pathways/superpathways are Signal Transduction and Response to elevated platelet cytosolic Ca2+. The drugs Everolimus and Platelet Aggregation Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and neutrophil, and related phenotypes are homeostasis/metabolism and cardiovascular system

Wikipedia: 75 Coronary thrombosis is defined as the formation of a blood clot inside a blood vessel of the heart. This... more...
Sources

Related Diseases for Coronary Thrombosis

About this section

Diseases related to Coronary Thrombosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 404)
# Related Disease Score Top Affiliating Genes
1 heparin-induced thrombocytopenia 30.3 ITGB3 ITGA2B F3
2 factor viii deficiency 30.3 VWF SERPINC1 F3
3 angina pectoris 30.1 TNNI3 PLAT P2RY12 F3 CRP
4 thrombophilia due to thrombin defect 30.0 VWF SERPINE1 SERPINC1 PLAT FGA F3
5 protein s deficiency 30.0 SERPINE1 SERPINC1 FGA F3
6 inferior myocardial infarction 29.9 TNNI3 PLG PLAT
7 antithrombin iii deficiency 29.9 SERPINC1 PLG FGA F3
8 thrombosis 29.8 VWF SERPINE1 SERPINC1 PLG PLAT P2RY12
9 essential thrombocythemia 29.8 VWF SERPINE1 PLAT ITGB3 ITGA2B GP1BA
10 hemophilia b 29.8 VWF SERPINC1 GP1BA FGA F3
11 coronary artery vasospasm 29.8 TNNI3 F3 CRP
12 polycythemia 29.8 ITGB3 F3 CRP
13 thrombocytosis 29.7 VWF SERPINC1 FGA F3 CRP
14 thrombophilia 29.7 VWF SERPINE1 SERPINC1 PLAT ITGB3 FGA
15 atherosclerosis susceptibility 29.7 VWF SERPINE1 PLAT F3 CRP
16 thrombocytopenic purpura, autoimmune 29.5 ITGB3 ITGA2B GP6 GP1BA F3
17 cardiac arrest 29.5 TNNI3 MIR499A CRP
18 splenic infarction 29.5 SERPINC1 F3 CRP
19 raynaud disease 29.5 VWF PLAT CRP
20 thrombotic thrombocytopenic purpura 29.5 VWF SERPINE1 SERPINC1 GP1BA F3
21 peptic ulcer disease 29.5 VWF PTGS2 F3 CRP
22 toxic shock syndrome 29.4 SERPINC1 F3 CRP
23 thrombocytopenia due to platelet alloimmunization 29.4 VWF ITGB3 ITGA2B GP1BA F3
24 hemiplegia 29.4 PLG PLAT CRP
25 behcet syndrome 29.4 VWF SERPINC1 F3 CRP
26 aphasia 29.4 PLG PLAT CRP
27 coronary stenosis 29.4 VWF TNNI3 SERPINE1 CRP
28 hyperhomocysteinemia 29.3 VWF SERPINE1 SERPINC1 PLAT CRP
29 von willebrand's disease 29.3 VWF SERPINC1 PLAT ITGA2B GP6 GP1BA
30 antiphospholipid syndrome 29.3 VWF SERPINE1 SERPINC1 PLAT GP1BA F3
31 acute anterolateral myocardial infarction 29.3 PLG ITGA2B CRP
32 covid-19 29.3 TNNI3 PLG F3 CRP
33 mitral valve insufficiency 29.2 TNNI3 F3 CRP
34 sickle cell anemia 29.2 VWF SERPINC1 F3 CRP
35 polycythemia vera 29.2 VWF SERPINC1 ITGB3 GP1BA F3 CRP
36 heart septal defect 29.1 SERPINC1 MIR499A F3 CRP
37 atrial fibrillation 29.1 VWF TNNI3 PLAT F3 CRP
38 purpura 29.0 VWF SERPINC1 ITGB3 ITGA2B GP1BA F3
39 aortic aneurysm 29.0 SERPINE1 MIR126 F3 CRP
40 aortic aneurysm, familial thoracic 1 28.9 VWF SERPINE1 PLG CRP
41 nephrotic syndrome 28.9 SERPINC1 PLG FGA F3 CRP
42 portal vein thrombosis 28.9 VWF SERPINC1 PLG F3 CRP
43 cardiac tamponade 28.8 TNNI3 PLG PLAT F3 CRP
44 arteries, anomalies of 28.8 TNNI3 PLG MIR499A MIR126 CRP
45 aortic valve disease 2 28.8 VWF TNNI3 MIR126 CRP
46 acute myocardial infarction 28.7 VWF TNNI3 SERPINE1 SERPINC1 PLAT MIR499A
47 endocarditis 28.7 TNNI3 SERPINE1 SERPINC1 PLAT ITGB3 GP1BA
48 intracranial embolism 28.7 VWF SERPINC1 PLG PLAT ITGA2B F3
49 infective endocarditis 28.6 VWF PLG ITGA2B GP1BA F3 CRP
50 atrial heart septal defect 28.6 VWF TNNI3 SERPINC1 PLG PLAT F3

Graphical network of the top 20 diseases related to Coronary Thrombosis:



Diseases related to Coronary Thrombosis
Sources

Symptoms & Phenotypes for Coronary Thrombosis

About this section

MGI Mouse Phenotypes related to Coronary Thrombosis:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.42 CRP F3 FGA GP1BA GP6 ITGA2B
2 cardiovascular system MP:0005385 10.34 CRP F3 FGA ITGA2B ITGB3 MIR126
3 cellular MP:0005384 10.27 F3 FGA GP1BA ITGA2B ITGB3 MIR126
4 nervous system MP:0003631 10.26 F3 FGA ITGA2B ITGB3 PLAT PLG
5 immune system MP:0005387 10.22 CRP F3 FGA GP6 ITGA2B ITGB3
6 muscle MP:0005369 10.16 F3 ITGB3 MIR499A PLAT PTGS2 SERPINC1
7 digestive/alimentary MP:0005381 10.13 FGA ITGA2B ITGB3 PLAT PLG PTGS2
8 hematopoietic system MP:0005397 10.03 F3 FGA GP1BA GP6 ITGA2B ITGB3
9 reproductive system MP:0005389 10.02 FGA GP6 ITGA2B ITGB3 MIR126 PLAT
10 respiratory system MP:0005388 9.97 F3 ITGB3 MIR126 PLAT PLG PTGS2
11 vision/eye MP:0005391 9.96 F3 FGA GP6 ITGB3 MIR126 PLAT
12 mortality/aging MP:0010768 9.83 F3 FGA GP6 ITGA2B ITGB3 MIR126
13 integument MP:0010771 9.4 F3 FGA GP6 ITGA2B ITGB3 MIR126
Sources

Drugs & Therapeutics for Coronary Thrombosis

About this section

Drugs for Coronary Thrombosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
2 Platelet Aggregation Inhibitors Phase 4
3 Immunosuppressive Agents Phase 4
4 Immunologic Factors Phase 4
5
Rivaroxaban Approved Phase 3 366789-02-8 9875401
6
Clopidogrel Approved Phase 3 120202-66-6, 113665-84-2 60606
7 Analgesics Phase 3
8 Antirheumatic Agents Phase 3
9 Fibrinolytic Agents Phase 3
10 Fibrin fragment D Phase 3
11 Neurotransmitter Agents Phase 3
12 Antipyretics Phase 3
13 Purinergic P2Y Receptor Antagonists Phase 3
14 Factor Xa Inhibitors Phase 3
15 Cyclooxygenase Inhibitors Phase 3
16 HIV Protease Inhibitors Phase 3
17 Anticoagulants Phase 3
18 Anti-Inflammatory Agents, Non-Steroidal Phase 3
19 Serine Proteinase Inhibitors Phase 3
20 Antithrombins Phase 3
21 Antithrombin III Phase 3
22 Analgesics, Non-Narcotic Phase 3
23 Anti-Inflammatory Agents Phase 3
24
protease inhibitors Phase 3
25
Serine Investigational, Nutraceutical Phase 3 56-45-1 5951
26
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
27 Immunoglobulins Phase 1, Phase 2
28 Antibodies Phase 1, Phase 2
29
Miconazole Approved, Investigational, Vet_approved 22916-47-8 4189
30
Clotrimazole Approved, Vet_approved 23593-75-1 2812
31
Thrombin Approved, Investigational
32 Antifungal Agents
33 Antibiotics, Antitubercular

Interventional clinical trials:

(show all 13)
# Name Status NCT ID Phase Drugs
1 A Clinical Evaluation of Dual Antiplatelet Therapy Duration Following Treatment With the Medtronic Endeavor Zotarolimus-eluting Coronary Stent Completed NCT00963781 Phase 4 Reduced duration (6 months) DAPT
2 Evaluation of Late Clinical Events After Drug-eluting Versus Bare-metal Stents in Patients at Risk: BAsel Stent Kosten Effektivitäts Trial - PROspective Validation Examination Part II (BASKET-PROVE II) Completed NCT01166685 Phase 4
3 Comparative Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control on the Gastric Lesions Induced by the Aspirin With the Low Dose Among Patients Treated With the Long Course Withdrawn NCT00713947 Phase 4 during one week for the active treatments;Pantoprazole;Placebo Formula 515
4 A Randomized Controlled Clinical Trial of PARIS Coronary Thrombosis Risk Score Combined With D-dimer to Guide New Oral Anticoagulant Antithrombotic Therapy in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention Not yet recruiting NCT05638867 Phase 3 Aspirin + Clopidogrel + Rivaroxaban;Aspirin + Clopidogrel
5 Evaluation of Neointimal Healing of Endothelial Progenitor Cell Capturing Sirolimus-Eluting (COMBO) Stent by Optical Coherence Tomography: the EGO-COMBO Pilot Study Completed NCT01274234 Phase 1, Phase 2
6 Periprocedural Myocardial Infarction: the Role of Human Neutrophil Peptide-1 to 3 Unknown status NCT02591264
7 Pilot Study Investigating the Use of a Variety of Assays to Detect Individual Response to Antiplatelet Therapy Unknown status NCT00327041
8 EKG Criteria and Identification of Acute Coronary Occlusion Unknown status NCT03863327
9 A Prospective Registry for the Use of CypherTM Sirolimus-Eluting Stents In Patients With Coronary Artery Disease Treated With Percutaneous Coronary Interventions at Scripps Clinic Completed NCT00714623
10 Prospective Evaluation of Acetyl-Coenzyme A Carboxylase Phosphorylation State in Platelets in Atherothrombotic Coronary Artery Disease. Completed NCT03034148
11 Study of Myeloid-related Protein 8/14 and Additional Biomarkers (Multi Marker Approach) for Early Diagnosis and Risk Stratification in Patients Presenting With Acute Chest Pain at the Emergency Department Completed NCT00657436
12 Mechanisms of Very Late Bioresorbable Scaffold Thrombosis Assessed by Optical Coherence Tomography: Insights From the International INVEST Registry Completed NCT03180931
13 Optical Frequency Domain Imaging-Quantified Intracoronary Thrombus Mass During Primary Percutaneous Coronary Intervention, Its Relationship With Antiplatelet Pretreatment Effect And Its Impact On Myocardial Reperfusion Completed NCT03342521

Search NIH Clinical Center for Coronary Thrombosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


heparin
heparin calcium
heparin sodium
HEPARIN SODIUM (BEEF LUNG)
heparin sodium, bovine
heparin sodium, porcine
Tenecteplase
Urokinase

Cochrane evidence based reviews: coronary thrombosis

Sources

Genetic Tests for Coronary Thrombosis

About this section
Sources

Anatomical Context for Coronary Thrombosis

About this section

Organs/tissues related to Coronary Thrombosis:

MalaCards : Heart, Lung, Neutrophil, Endothelial, Myeloid, Smooth Muscle, Lymph Node
Sources

Publications for Coronary Thrombosis

About this section

Articles related to Coronary Thrombosis:

(show top 50) (show all 2487)
# Title Authors PMID Year
1
[Annexin A5 inhibits homocysteine-induced tissue factor expression and activity in vascular smooth muscle cells]. 53 62
20137335 2009
2
Atherothrombosis: role of tissue factor; link between diabetes, obesity and inflammation. 53 62
17249334 2007
3
Rapid release of active tissue factor from human arterial smooth muscle cells under flow conditions. 53 62
16528008 2006
4
Detection of von Willebrand factor and tissue factor in platelets-fibrin rich coronary thrombi in acute myocardial infarction. 53 62
16377278 2006
5
[Regulatory effect of IL-10 on expression of tissue factor induced by IL-6 in peripheral blood mononuclear cells]. 53 62
15972146 2005
6
Angiographic demonstration of coronary dethrombosis with eptifibatide. 53 62
15156011 2004
7
Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. 53 62
14963043 2004
8
How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. 53 62
12808446 2003
9
Plasminogen activator inhibitor-1, which is released from blood product transfusions, might be associated with (sub)acute thrombosis after coronary dilatation and stenting: a case report. 53 62
12644882 2003
10
Glycoprotein IIIa Pl(A1/A2) polymorphism and sudden cardiac death. 53 62
11028489 2000
11
Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly. 53 62
10928474 2000
12
Polymorphisms in the 5' regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: the ECTIM and PATHROS studies. Etude Cas-Témoins de l'Infarctus du Myocarde. Paris Thrombosis case-control Study. 53 62
10712418 2000
13
The PlA2 polymorphism of the platelet glycoprotein IIIA gene as a risk factor for acute renal allograft rejection. 53 62
10589700 1999
14
Glycoprotein IIIa Pl(A) polymorphism associates with progression of coronary artery disease and with myocardial infarction in an autopsy series of middle-aged men who died suddenly. 53 62
10521390 1999
15
Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. 53 62
10199872 1999
16
Association between the ACE genotype and coronary artery disease. Insights from studies on restenosis, vasomotion and thrombosis. 53 62
9796837 1998
17
Coronary thrombosis associated with antithrombin-III deficiency. 53 62
9327319 1997
18
Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. 53 62
9012634 1997
19
Identification of active tissue factor in human coronary atheroma. 53 62
8822973 1996
20
Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis. 53 62
8735626 1996
21
Enhanced platelet aggregability under high shear stress after treadmill exercise in patients with effort angina. 53 62
8725732 1996
22
Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis. 53 62
7641354 1995
23
Novel antithrombotic approaches to coronary artery disease. 53 62
7863968 1995
24
Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration. 53 62
8026028 1994
25
Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries. 53 62
1451271 1992
26
Reduced synthesis of tissue plasminogen activator by vascular endothelium during acute myocardial infarction. 53 62
1497553 1992
27
Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis. 53 62
1606285 1992
28
Role of heparin in coronary thrombolysis. 53 62
1555478 1992
29
Thrombolytic effects of a novel modified tissue plasminogen activator, E6010, on coronary thrombosis in the pig. 53 62
1513078 1992
30
Coronary thrombosis after European adder bite in a patient on dual antiplatelet therapy: A case report. 62
36347271 2022
31
Incidence and timing of coronary thrombosis in Kawasaki disease patients with giant coronary artery aneurysm. 62
36455387 2022
32
Extensive right coronary artery thrombosis in a patient with COVID-19: A case report. 62
36387805 2022
33
Repeated Coronary Artery Thrombosis after mRNA-1273 COVID-19 Vaccination. 62
36440252 2022
34
The Challenge of High Coronary Thrombotic Events in Patients with ST-Segment Elevation Myocardial Infarction and COVID-19. 62
36362770 2022
35
Forensic autopsy-confirmed thrombosis-related deaths: the danger in the bones. 62
35962853 2022
36
Arterial and venous thromboembolism risk associated with blood eosinophils: A systematic review and meta-analysis. 62
36205251 2022
37
Synthetic cannabinoids and ST elevation myocardial infarction. 62
35545143 2022
38
A practical nomogram for predicting coronary thrombosis for Kawasaki disease patients with medium or large coronary artery aneurysm. 62
36151486 2022
39
A Peculiar Case of Recurrent Coronary Artery Thrombosis. 62
36304350 2022
40
Montelukast and Acute Coronary Syndrome: The Endowed Drug. 62
36145367 2022
41
New onset nonischemic cardiomyopathy post liver transplantation. 62
34799813 2022
42
Danshensu prevents thrombosis by inhibiting platelet activation via SIRT1/ROS/mtDNA pathways without increasing bleeding risk. 62
35777120 2022
43
Prognostic Implications of Neutrophil Extracellular Traps in Coronary Thrombi of Patients with ST-Elevation Myocardial Infarction. 62
34847588 2022
44
Minimally invasive treatment of left main coronary artery thrombosis in a young patient with COVID-19. 62
35793859 2022
45
TRAF3 promoted ROS-induced oxidative stress in model of cardiac infarction through the regulation of ULK1 ubiquitination. 62
35318880 2022
46
Daming capsule protects against myocardial infarction by promoting mitophagy via the SIRT1/AMPK signaling pathway. 62
35676781 2022
47
Cardiovascular complications of COVID-19. 62
35638457 2022
48
Transcatheter aspiration of a thrombus and percutaneous transluminal coronary recanalization for ST-segment elevation myocardial infarction related to coronavirus disease 2019. 62
35035630 2022
49
Inhibitory role of recombinant neorudin on canine coronary artery thrombosis. 62
35505637 2022
50
Epidemiology and Management of ST-Segment-Elevation Myocardial Infarction in Patients With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry. 62
35470683 2022
Sources

Variations for Coronary Thrombosis

About this section
Sources

Expression for Coronary Thrombosis

About this section
Search GEO for disease gene expression data for Coronary Thrombosis.
Sources

Pathways for Coronary Thrombosis

About this section

Pathways related to Coronary Thrombosis according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Signal Transduction 66
13.67 VWF SERPINE1 PLG PLAT P2RY12 ITGB3
2
Response to elevated platelet cytosolic Ca2+ 66
Show member pathways
 13 F3 FGA GP1BA GP6 ITGA2B ITGB3
3
Extracellular matrix organization 66
Show member pathways
 12.55 FGA ITGA2B ITGB3 PLG SERPINE1 VWF
4
Complement cascade 66
Show member pathways
 12.52 PLG ITGB3 ITGA2B FGA CRP
5
Oncogenic MAPK signaling 66
Show member pathways
 12.03 FGA ITGA2B ITGB3 VWF
6
ECM proteoglycans 66
Show member pathways
 11.99 VWF SERPINE1 ITGB3 ITGA2B FGA
7
Adhesion 3
11.9 SERPINE1 PLG ITGB3 F3
8
Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) 66
Show member pathways
 11.74 VWF SERPINE1 SERPINC1 PLG PLAT GP6
9
Angiogenesis (CST) 3
11.71 VWF PTGS2 ITGB3 F3
10
Integrin signaling 66
Show member pathways
 11.64 VWF ITGB3 ITGA2B GP1BA FGA
11
Cell adhesion_ECM remodeling 22
11.55 SERPINE1 PLG PLAT
12
Cell adhesion_Plasmin signaling 22
11.44 PLG PLAT FGA
13
Fibrin complement receptor 3 signaling pathway 74
11.37 PLG PLAT FGA
14
Beta3 integrin cell surface interactions 61
11.3 ITGB3 ITGA2B FGA
15
Heparin-induced Thrombocytopenia Pathway, Adverse Drug Reaction 60
11.27 ITGB3 ITGA2B F3
16
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling 61
11.21 SERPINE1 PLG ITGB3 FGA
17
Platelet Aggregation Inhibitor Pathway, Pharmacodynamics 60
11.14 VWF P2RY12 ITGB3 ITGA2B GP6 FGA
18
Beta2 integrin cell surface interactions 61
11.13 PLAT GP1BA FGA
19
Platelet Adhesion to exposed collagen 66
Show member pathways
 11.08 VWF GP6 GP1BA
20
Dissolution of Fibrin Clot 66
10.69 SERPINE1 PLG PLAT
21
COVID-19, thrombosis and anticoagulation 74
10.44 PLG FGA
Sources

GO Terms for Coronary Thrombosis

About this section

Cellular components related to Coronary Thrombosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.41 FGA GP1BA GP6 ITGA2B ITGB3 PLAT
2 extracellular space GO:0005615 10.28 CRP F3 FGA GP1BA MIR126 PLAT
3 blood microparticle GO:0072562 10.01 SERPINC1 PLG ITGA2B FGA
4 cell surface GO:0009986 9.91 F3 FGA GP1BA GP6 ITGA2B ITGB3
5 platelet alpha granule lumen GO:0031093 9.76 VWF SERPINE1 PLG FGA
6 serine protease inhibitor complex GO:0097180 9.62 SERPINE1 PLAT
7 collagen-containing extracellular matrix GO:0062023 9.5 VWF SERPINF1 SERPINE1 SERPINC1 PLG PLAT

Biological processes related to Coronary Thrombosis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of angiogenesis GO:0045766 10.02 SERPINE1 MIR126 ITGB3 F3
2 platelet activation GO:0030168 10 FGA GP1BA GP6 ITGB3 P2RY12 VWF
3 platelet aggregation GO:0070527 9.92 P2RY12 ITGB3 GP1BA FGA
4 negative regulation of endothelial cell apoptotic process GO:2000352 9.85 SERPINE1 MIR126 FGA
5 negative regulation of fibrinolysis GO:0051918 9.85 SERPINE1 PLG PLAT
6 fibrinolysis GO:0042730 9.85 SERPINE1 PLG PLAT GP1BA FGA
7 negative regulation of plasminogen activation GO:0010757 9.8 SERPINE1 PLAT
8 trans-synaptic signaling by BDNF, modulating synaptic transmission GO:0099183 9.73 PLG PLAT
9 negative regulation of synaptic transmission, dopaminergic GO:0032227 9.71 PTGS2 SLC6A4
10 hemostasis GO:0007599 9.65 F3 FGA GP1BA GP6 P2RY12 PLG
11 blood coagulation GO:0007596 9.55 VWF SERPINC1 PLG PLAT P2RY12 ITGB3

Molecular functions related to Coronary Thrombosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.32 VWF SERPINE1 SERPINC1 ITGB3 F3
Sources

Sources for Coronary Thrombosis

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....